Coloplast AS Class B

COLO B: XCSE (DNK)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
CTkLOCK|W#&@LOCK|LY$#BG

Coloplast Earnings: New Leadership Intends to Move Forward With Urgency

Coloplast posted fiscal second-quarter performance that was fairly consistent with recent quarters as organic revenue rose 6% thanks to strength in continence care and advanced wound care. However, weakness in ostomy and interventional urology is likely to linger.

Sponsor Center